6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis.

Medicine (Baltimore) · 2021 · PMC7969267 · PMID 33725875

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

very close to statistical significanceno p-value reported

Due to the limited sample, no statistically significant improvement of 6-month trastuzumab treatment compared to standard of care (12 months), but the P values are very close to statistical significance.

also in 143 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.